LIVE WEBINAR: Thursday, November 5, 2020, 5:00 PM – 6:00 PM Eastern Time

What Advanced Practice Professionals Need to Know about Caring for Patients with Locally Advanced Non-Small Cell Lung Cancer

A Live CE Webinar for Nurse Practitioners and Physician Assistants

Join us on Thursday, November 5th for this CE-accredited live webinar
5:00 PM – 6:00 PM ET

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.


Ramaswamy Govindan, MD
Professor of Medicine
Director, Section of Oncology
Anheuser-Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP
Clinical Operations Manager
Thoracic, Neuro, Uro and Radiation Oncology
Nurse Practitioner, Thoracic Oncology
Stanford Health Care
Palo Alto, California

Rasheda Persinger, NP-C
Medical Oncology Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Washington, DC

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Topics to Be Discussed

  • Design, eligibility criteria and long-term efficacy and safety findings from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy (CRT) for patients with unresectable Stage III non-small cell lung cancer (NSCLC)
  • Benefit observed with durvalumab in prespecified subgroups in the PACIFIC trial; patient selection for and practical implementation of sequential durvalumab after successful CRT
  • Optimal timing for the initiation of durvalumab consolidation; impact of underlying CRT-associated pneumonitis or esophagitis on the potential introduction of anti-PD-L1 therapy
  • Spectrum, incidence, time course and severity of toxicities, including immune-related adverse events (irAEs), with durvalumab in patients with locally advanced NSCLC; frequency of dose interruption or treatment discontinuation
  • Optimal management of irAEs and other toxicities observed with durvalumab consolidation
  • Rationale for, available data with and ongoing investigation of anti-PD-1/PD-L1 antibodies administered concurrently with definitive CRT for unresectable Stage III NSCLC

Target Audience
This activity has been designed to meet the educational needs of advanced practice professionals, including nurse practitioners and physician assistants, involved in the treatment of locally advanced non-small cell lung cancer (NSCLC).

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced NSCLC, and consider this information when counseling patients.
  • Review the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Develop an understanding of which clinical and biologic factors (eg, chemoradiation therapy-related toxicities, PD-L1 status, EGFR and ALK status) potentially affect the decision to use anti- PD-L1 antibody consolidation therapy for unresectable Stage III NSCLC, and apply this information to better counsel patients about current therapeutic recommendations.
  • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and manage these toxicities.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for localized or locally advanced NSCLC, and counsel appropriate patients about availability and participation.
  • Identify opportunities to enhance the collaborative role of oncology nurses, nurse practitioners and physician assistants in the comprehensive biopsychosocial care of patients with locally advanced NSCLC to optimize clinical and quality-of-life outcomes.
Accreditation and Credit Designation Statements
NCPD: Research To Practice is accredited as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity for 1 contact hour is provided by Research To Practice.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. The credit form links will be emailed to participants within 24 hours of the activity.

AANP: This activity will be submitted to the American Association of Nurse Practitioners for approval of up to 1 contact hour of accredited education.

AAPA: This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit™. PAs should claim only the credit commensurate with the extent of their participation. Approval is valid from 11/5/2020 to 11/5/2021. AAPA reference number: CME-201219.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the ANCC. Any off-label use as declared by the FDA will be identified.

Research To Practice NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.